Archives
|
Entry
|
Blogger
|
Date
▴
|
Location
|
|
Seattle’s Top 10 Innovation Stories of the Half-Year (and Others We Just Plain Liked)
|
Gregory T. Huang |
12/31/08 |
Seattle
|
|
New RNAi Drugs, Major Cutbacks at Targanta, Big Partnerships for Arqule and Archemix, & More Boston-Area Life Sciences News
|
Wade Roush |
12/24/08 |
Boston
|
|
Tysabri Patient Dies of Brain Infection, First Death Since Drug Re-Introduced
|
Luke Timmerman |
12/19/08 |
Boston
|
|
Tysabri Patient Diagnosed With PML
|
Luke Timmerman |
12/15/08 |
Boston
|
|
Biogen Idec VC Group Sees Opportunity in Tough Market, Has $100M New Allocation to Invest in Biotech Firms
|
Ryan McBride |
12/12/08 |
San Diego
|
|
Tysabri’s Roots at the “Hutch,” MediQuest Spurned by FDA, ZymoGenetics Drug Passes Test, & More Seattle-Area Life Sciences News
|
Luke Timmerman |
11/06/08 |
Seattle
|
|
A Trio of Tysabri Stories, Genzyme’s Big Deal with Osiris, A Peek Inside a Winning Hedge Fund, & More Life Sciences News
|
Rebecca Zacks |
11/05/08 |
Boston
|
|
Tysabri: The Big Multiple Sclerosis Drug That Emerged From “The Hutch”
|
Luke Timmerman |
11/04/08 |
Seattle
|
|
Democratic Party Fundraiser Dies, After Friends and Family Pushed To Get Him Tysabri
|
Luke Timmerman |
10/31/08 |
Boston
|
|
Biogen Idec, Elan’s Tysabri Linked to First U.S. Case of Brain Infection
|
Luke Timmerman |
10/29/08 |
Boston
|
|
Dying Cancer Patient Gets Tysabri After Biogen Idec’s Earlier Denial
|
Luke Timmerman |
10/16/08 |
Boston
|
|
Biogen Turns Down Dying Patient’s Request For Tysabri—and Explains Why
|
Luke Timmerman |
10/14/08 |
Boston
|
|
Biogen Idec, Elan Start First Cancer Trial With Tysabri
|
Luke Timmerman |
09/05/08 |
Boston
|
|
Biogen Idec Testing Regenerative Medicine Drug to Reverse the Path of Multiple Sclerosis
|
Luke Timmerman |
08/27/08 |
Boston
|
|
FDA Doesn’t Appear Overly Alarmed by Recent Cases of Brain Disease Associated With Tysabri; Working with Biogen Idec and Elan to Update Labeling
|
Luke Timmerman |
08/26/08 |
Boston
|
|
Taligen CEO Aims to Develop Drugs For Inflammatory Diseases, Build Company in Cambridge
|
Luke Timmerman |
08/14/08 |
Boston
|
|
Icahn Ups Biogen Idec Stake to 6 Percent—Bought Big on Tysabri Woes
|
Ryan McBride |
08/12/08 |
Boston
|
|
Vertex Cystic Fibrosis Program on the Rise, Biogen and Partner Fall on Tysabri News, Alnylam Stakes RNAa IP Claim, & More Life Sciences News
|
Rebecca Zacks |
08/06/08 |
Boston
|
|
Biogen Idec, Elan Shares Plummet on News of Two PML Cases With Tysabri
|
Luke Timmerman |
08/01/08 |
Boston
|
|
Biogen Idec, Elan Report Two New Cases of Rare Brain Infection in Tysabri Patients
|
Luke Timmerman |
07/31/08 |
Boston
|
|
Biogen Idec, Elan Say More Than 31,800 Patients Taking Tysabri For MS
|
Luke Timmerman |
07/22/08 |
Boston
|
|
Biogen Idec Isn’t Sweating Possible Sale of Genentech to Roche
|
Luke Timmerman |
07/22/08 |
Boston
|
|
Genzyme Reaching For a Slice From Biogen’s Breadbasket, Multiple Sclerosis Drugs
|
Luke Timmerman |
07/17/08 |
Boston
|
|
Biogen’s Busy Week, Alnylam’s Big Announcement, Targanta’s and Momenta’s Growing Executive Ranks, & More Life Sciences News
|
Rebecca Zacks |
03/05/08 |
Boston
|
|
Biogen Bouncing Back From Tysabri Warning News
|
Rebecca Zacks |
02/28/08 |
Boston
|
|
Biogen Idec’s Tysabri Approved for Crohn’s
|
Rebecca Zacks |
01/14/08 |
Boston
|
|
Perceived Risk, Culture Clash Did in Biogen Idec Sale, CEO Asserts
|
Henry Johnson |
01/11/08 |
Boston
|
|
Page 1 of
1 |
|
Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.
© 2007-2008 Xconomy. All rights reserved.
Site designed by
Matthew Bouchard, produced by
Andrew Koyfman,
and powered by WordPress.
